Release Date: June 6, 2022
Expiration Date: June 30, 2022
Activity Overview
This educational activity is an archive of the live virtual presentation held on June 5, 2022.
For more information about this educational activity, the faculty, and disclosures, please click here.
Target Audience
This educational activity is directed toward physicians involved in the treatment of MPNs.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Determine factors that inform care plans for patients with MF and PV based on genetics, risk stratification, and symptom burden
- Explain the mechanistic rationale for the application of therapeutic approaches for the management of MPNs
- Describe evidence from investigations on treatment approaches for MF and PV, including how these findings can inform proactive strategies planning to manage treatment-related toxicities
- Devise strategies to integrate emerging evidence to manage clinical scenarios commonly encountered in the care of patients with MPNs along the disease continuum
Ruben A. Mesa, MD, FACP
Executive Director
Mays Cancer Center
UT Health San Antonio MD Anderson Cancer Center
Mays Family Foundation Distinguished University Presidential Chair
Professor of Medicine
San Antonio, TX
Disclosures: Grant/Research Support: AbbVie, Celgene, Constellation, CTI, Genotech, Incyte, Mays Cancer Center P30 Cancer Center, National Cancer Institute support grant (CA054174), Promedior, Samus Therapeutics; Consultant: Constellation, La Jolla Pharmaceutical, Novartis, Sierra Oncology.
Jamile M. Shammo, MD, FASCP, FACP
Professor of Medicine and Pathology
Rush University
Chicago, IL
Disclosures: Grant/Research Support: AbbVie, Alexion, AstraZeneca, Bristol Myers Squibb, Incyte, CTI BioPharma, Kartos Therapeutics, Stemline Therapeutics; Consultant: AbbVie, Alexion, Apellis, Bristol Myers Squibb, Incyte, CTI BioPharma, Novartis, Sanofi; Speakers’ Bureau: Alexion, Blueprint Medicines, Bristol Myers Squibb, Incyte, Sanofi; Shareholder: AbbVie, Baxter; Other: DSMB chair: NS Pharma; DSMB member: Apellis.
Naveen Pemmaraju, MD
Associate Professor
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosures: Grant/Research Support: US Department of Defense; Consultant: AbbVie, Aptitude Health, Astellas Pharma US, Blueprint Medicines, Bristol Myers Squibb, Celgene, Cimeio Therapeutics AG, ClearView Healthcare Partners, CTI BioPharma, DAVA Oncology, ImmunoGen, Incyte, Intellisphere, Novartis AG, Novartis Pharmaceuticals Corp, OncLive®, Patient Power, PharmaEssentia, Protagonist Therapeutics, Sanofi-Aventis, Stemline Therapeutics, TotalCME; Shareholder: Karger Publishers; Other: Scientific/advisory committee member: Cancer.Net, CareDx, CTI BioPharma, EUSA Pharma, Novartis Pharmaceuticals, Pacylex Pharmaceuticals, PharmaEssentia; Speaker/preceptorship: AbbVie, Aplastic Anemia & MDS International Foundation, Curio Science LLC, DAVA Oncology, Imedex, Magdalen Medical Publishing, Medscape, Neopharm, PeerView Institute for Medical Education, Physicians Education Resource® (PER®), Postgraduate Institute for Medicine, Stemline Therapeutics.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
